Purpose: We hypothesized that T-cell immune interaction affects tumor development and thus clinical outcome. Therefore, we examined the clinical impact of human leukocyte antigen (HLA) class I tumor cell expression and regulatory T-cell (Treg) infiltration in breast cancer.

Experimental Design: Our study population (N = 677) is consisted of all early breast cancer patients primarily treated with surgery in our center between 1985 and 1994. Formalin-fixed, paraffin-embedded tumor tissue was immunohistochemically stained using HCA2, HC10, and Foxp3 monoclonal antibodies.

Results: HLA class I expression was evaluated by combining results from HCA2 and HC10 antibodies and classified into three groups: loss, downregulation, and expression. Remarkably, only in patients who received chemotherapy, both presence of Treg (P = 0.013) and higher HLA class I expression levels (P = 0.002) resulted in less relapses, independently of other variables. Treg and HLA class I were not of influence on clinical outcome in patients who did not receive chemotherapy.

Conclusions: We showed that HLA class I and Treg affect prognosis exclusively in chemotherapy-treated patients and are therefore one of the few predictive factors for chemotherapy response in early breast cancer patients. Chemotherapy may selectively eliminate Treg, thus enabling CTLs to kill tumor cells that have retained HLA class I expression. As a consequence, HLA class I and Treg can predict response to chemotherapy with high discriminative power. These markers could be applied in response prediction to chemotherapy in breast cancer patients. Clin Cancer Res; 16(4); 1272–80

Translational Relevance

Predictive factors for chemotherapy response in breast cancer are few and mostly lack discriminative power or a biological explanation. Previous studies have shown that chemotherapeutical treatment positively influences the host immune system through immunosuppressive regulatory T-cell (Treg) arrest, which may result in enhanced expansion and function of CTLs. Therefore, we hypothesized that presence of Tregs and retained expression of human leukocyte antigen class I before chemotherapy administration would result in a better treatment response of patients. Indeed, we showed in our study that human leukocyte antigen class I expression and Treg infiltration of tumors have high prognostic power, specifically among chemotherapy-treated patients. To our best knowledge, there are no reports on predictive markers for chemotherapy response in breast cancer patients that have such high discriminative power and such solid biological explanation. Therefore, these markers may be suitable for response prediction to chemotherapy in breast cancer patients.

Breast cancer is the most common cancer in women: it affects one in nine women. Systemic treatment improves disease-free survival and overall survival in patients with early breast cancer (1). Decisions about this systemic therapy are depending on prognostic and predictive factors, which divide patients into different risk groups (2). With the current classifications, however, prediction of outcome is still not optimal and additional prognostic and predictive factors are needed to improve tailored treatment.

It is widely accepted that the adaptive immune system plays an important role in controlling tumor growth and spread (3). CTLs are capable to affect tumor development. However, because of their intrinsic genetic unstable nature, tumor cells may acquire properties to escape from CTL recognition. Among these properties are downregulation or complete loss of human leukocyte antigen (HLA) class I expression. In addition, immunosuppressive regulatory T cells (Treg) may be induced (4).

HLA class I molecules play a pivotal role in CTL-mediated immune responses and have been found to be a prognostic factor in various types of cancer (57). Previous studies have shown that HLA class I expression is frequently downregulated in breast cancer (8, 9). However, the reports on prognostic influence of HLA class I expression in breast cancer have contradictory results (1012). Some found no significant correlation between percentage of tumor cells expressing HLA class I and survival of breast cancer patients (10, 12). In contrast, another study found that total loss of HLA class I was an independent indicator of good prognosis (11).

Tregs act as immunosuppressors and maintain immunologic self-tolerance. Numbers of tumor-infiltrating Treg are known to be increased in several malignancies, and a correlation was found with worse disease stage and prognosis in cancer (13, 14). In breast cancer, the presence of Treg in the tumor environment has been found in several studies (1517). Moreover, these studies found a higher prevalence of Treg in tumor microenvironment and in peripheral blood of patients suffering breast cancer compared with healthy donors (1517). One study found higher numbers of Treg to be correlated with worse disease stage and shorter survival (15). Interestingly, chemotherapy has been found to be involved in presence and prognostic influence of Treg (16). The numbers of Treg in tumor tissue decreased after chemotherapy administration, and there was an association between disappearance of Treg and pathologic complete response to preoperative chemotherapy.

The purpose of our study was to analyze the prognostic relevance of HLA class I expression and Treg infiltration in a large cohort of early breast cancer patients. In addition, we explored the predictive value of these markers for chemotherapy response.

Patients and tumors

The patient population is composed of all nonmetastasized breast cancer patients primarily treated with surgery in the Leiden University Medical Center between 1985 and 1994 (N = 677). Patients with bilateral tumors or a history of cancer, other than basal cell carcinoma or cervical carcinoma in situ, were excluded. The following data were known: age, tumor differentiation grade and morphology, TNM stage, local and systemic therapy, locoregional/distant tumor recurrence, secondary tumor, alive/death, estrogen receptor, progesterone receptor, Ki67, and human epidermal growth factor receptor 2.5

5J.G.H. van Nes, E.M. de Kruijf, D. Faratian, C.J.H. van de Velde, H. Putter, C. Falconer, V.T.H.B.M. Smit, C. Kay, M.J. van de Vijver, P.J.K. Kuppen, J.M.S. Bartlett. COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients, submitted.

All tumors were graded according to current pathologic standards by one pathologist (V.T.H.B.M. Smit).

Antibodies

The mouse monoclonal antibodies HCA2 and HC10, which recognize HLA class I heavy chains (kindly provided by Prof. Dr. J. Neefjes), were used. The reactivity spectrum of HCA2 is composed of all HLA-A chains (except HLA-A24), as well as some HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G chains (18, 19). HC10 reacts mostly with HLA-B and HLA-C heavy chains and some HLA-A (HLA-A10, HLA-A28, HLA-A29, HLA-A30, HLA-A31, HLA-A32, HLA-A33; refs. 20, 21). Mouse antibodies against human Foxp3 (ab20034 clone 236A/E7; AbCam) were used for Treg identification. The reactivity spectrum of Foxp3 is composed of Treg and may include small numbers of CD8+ cells (22), but thus far, it is the best single marker of Treg (23).

Immunohistochemistry

For HLA class I staining, slides of 4 μm were cut from a priory constructed tissue microarray. For staining of Treg sections, 4-μm sections were cut from the original formalin-fixed, paraffin-embedded tumor blocks. Tissue sections were deparaffinized and rehydrated. Endogenous peroxidase was blocked for 20 min in hydrogen peroxide–methanol. For antigen retrieval, 0.01 mol/L citrate buffer (pH 6.0) was used for 10 min at maximum power in a microwave oven. Sections were incubated overnight with HCA2 or HC10 at room temperature using predetermined optimal concentrations. After incubation with secondary antibody envision anti-mouse (Dako Cytomation K4001), sections were visualized using 3,3′-diaminobenzidine solution (25 mL 3,3′-diaminobenzidine in 225 mL 0.05 mol/L Tris-HCl). Tissue sections were counterstained with hematoxylin, dehydrated, and mounted in malinol. All slides were stained simultaneously to avoid interassay variation. For each patient, normal epithelium, stromal cells, or lymphoid cells served as internal positive control for HLA class I antibody reactivity. Slides from human tonsil tissue served as positive control for Treg staining. For each staining, slides that did undergo the whole immunohistochemical staining procedure but without primary antibodies served as negative controls.

Evaluation of immunostaining

Microscopic analysis of HCA2 and HC10 was assessed by two independent observers (E.M. de Kruijf and Q.R.J.G. Tummers) in a blinded manner. Percentage of tumor cells that showed membranous staining was assessed. HCA2 and HC10 staining were scored in five categories according to the defined standard method of the International HLA and Immunogenetics Workshop (score 1, 0-5% of tumor cells positively stained; score 2, 5-25%; score 3, 25-50%; score 4, 50-75%; score 5, 75-100%; ref. 24). Quantification of Treg within the tumor was microscopically assessed in 10 high-power fields by two observers (E.M. de Kruijf, 100%; A. Sajet, 30%) in a blinded manner. Treg was scored into two categories: absence and presence of Treg infiltration.

Statistical analysis

Statistical analyses were done using the statistical package SPSS (version 15.0 for Windows; SPSS, Inc.). Cohen's κ coefficient revealed a satisfactory agreement in classification (κ = 0.73). The χ2 test was used to evaluate associations between various clinicopathologic variables and HLA class I expression and infiltration of Treg. Relapse-free period was the time from date of surgery until a locoregional recurrence and/or distance recurrence, whichever came first. Clinical follow-up policy was equal for all patients in the study. Overall survival was defined from date of surgery until death. The Kaplan-Meier method was used for calculation of survival probabilities and the log-rank test for comparison of survival curves. Relapse-free period is reported as cumulative incidence function after accounting for death as competing risk (25). Cox regression was used for univariate and multivariate analyses for relapse-free period and overall survival. Significant or close-to-significant variables (P < 0.1) in univariate analysis were included in multivariate analysis. To analyze the predictive effect of HLA class I and Treg, analyses were done and stratified for adjuvant chemotherapy administration.

Patient and tumor characteristics

Tumor material was available and incorporated in the tissue microarray of 86% (574 of 677) of the patients. Clinicopathologic and treatment characteristics are shown in Table 1. Median age of patients was 57 years (range, 23-96 years). Median follow-up of patients alive was 19 years (range, 0-23 years). Chemotherapy treatment is consisted of a combination of cytostatic drugs always containing cyclophosphamide.

Table 1.

Correlations between HLA class I expression and presence of Treg and well-established prognostic factors using χ2 test

TotalHLA Class ITreg
LossDownregulationExpressionAbsencePresence
Age (y)    P = 0.449  P = 0.902 
    <40 48 (8.4) 8 (6.6) 15 (7.5) 19 (9.4) 24 (7.5) 21 (8.8) 
    40-50 145 (25.3) 37 (30.3) 58 (29.0) 44 (21.8) 84 (26.2) 61 (25.5) 
    50-60 132 (23.0) 31 (25.4) 42 (21.0) 45 (22.3) 77 (24.1) 53 (22.2) 
    >60 249 (43.4) 46 (37.7) 85 (42.5) 94 (46.5) 135 (42.2) 104 (43.5) 
Grade    P <0.001  P = 0.047 
    I 80 (14.2) 28 (23.7) 26 (13.1) 16 (8.0) 52 (16.5) 27 (11.4) 
    II 282 (49.9) 55 (46.6) 114 (57.6) 87 (43.3) 163 (51.7) 113 (47.7) 
    III 203 (35.9) 35 (29.7) 58 (29.3) 98 (48.8) 100 (31.7) 97 (40.9) 
Histologic type    P = 0.135  P = 0.290 
    Ductal 513 (89.4) 102 (86.4) 178 (89.9) 190 (94.5) 286 (90.8) 215 (90.3) 
    Lobular 46 (8.0) 14 (11.9) 16 (8.1) 10 (5.0) 27 (8.6) 18 (7.6) 
    Other 7 (1.2) 2 (1.7) 4 (2.0) 1 (0.5) 2 (0.6) 5 (2.1) 
Tumor stage    P = 0.760  P = 0.850 
    pT1 211 (38.0) 46 (39.3) 73 (37.4) 71 (36.0) 120 (38.7) 87 (37.5) 
    pT2 272 (49.0) 55 (47.0) 92 (47.2) 103 (52.3) 151 (48.7) 112 (48.3) 
    pT3/4 72 (13.0) 16 (13.7) 30 (15.4) 23 (11.7) 39 (12.6) 33 (14.2) 
Nodal stage    P = 0.871  P = 0.831 
    pN0 307 (55.1) 64 (53.3) 107 (55.4) 111 (56.3) 170 (54.5) 128 (55.4) 
    pN+ 250 (43.6) 56 (46.7) 86 (44.6) 86 (43.7) 142 (45.5) 103 (44.6) 
Estrogen receptor    P = 0.004  P = 0.465 
    Negative 203 (37.6) 37 (30.8) 64 (33.0) 93 (46.5) 109 (36.3) 88 (39.5) 
    Positive 337 (62.4) 83 (69.2) 130 (67.0) 107 (53.5) 191 (63.7) 135 (60.5) 
Progesterone receptor    P <0.001  P = 0.140 
    Negative 223 (41.6) 44 (37.6) 64 (32.8) 105 (52.5) 116 (38.8) 100 (45.2) 
    Positive 313 (58.4) 73 (62.4) 131 (67.2) 95 (47.5) 183 (61.2) 121 (54.8) 
Ki67 expression    P = 0.161  P = 0.001 
    Negative 458 (85.4) 103 (88.0) 169 (87.1) 161 (81.3) 270 (90.0) 176 (80.0) 
    Positive 78 (14.6) 14 (12.0) 25 (12.9) 37 (18.7) 30 (10.0) 44 (20.0) 
HER2 overexpression    P = 0.147  P = 0.403 
    No overexpression 378 (89.6) 92 (94.8) 128 (87.7) 148 (88.1) 213 (88.8) 157 (91.3) 
    Overexpression 44 (10.4) 5 (5.2) 18 (12.3) 20 (11.9) 27 (11.2) 15 (8.7) 
Local therapy    P = 0.051  P = 0.985 
    MST - radiotherapy 223 (38.9) 46 (37.7) 75 (37.5) 85 (42.1) 125 (39.2) 90 (38.0) 
    MST + radiotherapy 108 (18.8) 25 (20.5) 27 (13.5) 46 (22.8) 60 (18.8) 44 (18.6) 
    BCS - radiotherapy 5 (0.9) 2 (1.6) 2 (1.0) 0 (0) 3 (0.9) 2 (0.8) 
    BCS + radiotherapy 238 (41.5) 49 (40.2) 96 (48.0) 71 (35.1) 131 (41.1) 101 (42.6) 
Systemic therapy    P = 0.426  P = 0.294 
    Chemotherapy 112 (19.5) 20 (16.4) 39 (19.5) 48 (23.8) 64 (20.0) 48 (20.1) 
    Endocrine therapy5 75 (13.1) 12 (9.8) 25 (12.5) 28 (13.9) 49 (15.3) 24 (10.0) 
    Both 18 (3.1) 3 (2.5) 9 (4.5) 6 (3.0) 11 (3.4) 7 (2.9) 
    No systemic therapy 369 (64.3) 87 (71.3) 127 (63.5) 120 (59.4) 196 (61.2) 160 (66.9) 
TotalHLA Class ITreg
LossDownregulationExpressionAbsencePresence
Age (y)    P = 0.449  P = 0.902 
    <40 48 (8.4) 8 (6.6) 15 (7.5) 19 (9.4) 24 (7.5) 21 (8.8) 
    40-50 145 (25.3) 37 (30.3) 58 (29.0) 44 (21.8) 84 (26.2) 61 (25.5) 
    50-60 132 (23.0) 31 (25.4) 42 (21.0) 45 (22.3) 77 (24.1) 53 (22.2) 
    >60 249 (43.4) 46 (37.7) 85 (42.5) 94 (46.5) 135 (42.2) 104 (43.5) 
Grade    P <0.001  P = 0.047 
    I 80 (14.2) 28 (23.7) 26 (13.1) 16 (8.0) 52 (16.5) 27 (11.4) 
    II 282 (49.9) 55 (46.6) 114 (57.6) 87 (43.3) 163 (51.7) 113 (47.7) 
    III 203 (35.9) 35 (29.7) 58 (29.3) 98 (48.8) 100 (31.7) 97 (40.9) 
Histologic type    P = 0.135  P = 0.290 
    Ductal 513 (89.4) 102 (86.4) 178 (89.9) 190 (94.5) 286 (90.8) 215 (90.3) 
    Lobular 46 (8.0) 14 (11.9) 16 (8.1) 10 (5.0) 27 (8.6) 18 (7.6) 
    Other 7 (1.2) 2 (1.7) 4 (2.0) 1 (0.5) 2 (0.6) 5 (2.1) 
Tumor stage    P = 0.760  P = 0.850 
    pT1 211 (38.0) 46 (39.3) 73 (37.4) 71 (36.0) 120 (38.7) 87 (37.5) 
    pT2 272 (49.0) 55 (47.0) 92 (47.2) 103 (52.3) 151 (48.7) 112 (48.3) 
    pT3/4 72 (13.0) 16 (13.7) 30 (15.4) 23 (11.7) 39 (12.6) 33 (14.2) 
Nodal stage    P = 0.871  P = 0.831 
    pN0 307 (55.1) 64 (53.3) 107 (55.4) 111 (56.3) 170 (54.5) 128 (55.4) 
    pN+ 250 (43.6) 56 (46.7) 86 (44.6) 86 (43.7) 142 (45.5) 103 (44.6) 
Estrogen receptor    P = 0.004  P = 0.465 
    Negative 203 (37.6) 37 (30.8) 64 (33.0) 93 (46.5) 109 (36.3) 88 (39.5) 
    Positive 337 (62.4) 83 (69.2) 130 (67.0) 107 (53.5) 191 (63.7) 135 (60.5) 
Progesterone receptor    P <0.001  P = 0.140 
    Negative 223 (41.6) 44 (37.6) 64 (32.8) 105 (52.5) 116 (38.8) 100 (45.2) 
    Positive 313 (58.4) 73 (62.4) 131 (67.2) 95 (47.5) 183 (61.2) 121 (54.8) 
Ki67 expression    P = 0.161  P = 0.001 
    Negative 458 (85.4) 103 (88.0) 169 (87.1) 161 (81.3) 270 (90.0) 176 (80.0) 
    Positive 78 (14.6) 14 (12.0) 25 (12.9) 37 (18.7) 30 (10.0) 44 (20.0) 
HER2 overexpression    P = 0.147  P = 0.403 
    No overexpression 378 (89.6) 92 (94.8) 128 (87.7) 148 (88.1) 213 (88.8) 157 (91.3) 
    Overexpression 44 (10.4) 5 (5.2) 18 (12.3) 20 (11.9) 27 (11.2) 15 (8.7) 
Local therapy    P = 0.051  P = 0.985 
    MST - radiotherapy 223 (38.9) 46 (37.7) 75 (37.5) 85 (42.1) 125 (39.2) 90 (38.0) 
    MST + radiotherapy 108 (18.8) 25 (20.5) 27 (13.5) 46 (22.8) 60 (18.8) 44 (18.6) 
    BCS - radiotherapy 5 (0.9) 2 (1.6) 2 (1.0) 0 (0) 3 (0.9) 2 (0.8) 
    BCS + radiotherapy 238 (41.5) 49 (40.2) 96 (48.0) 71 (35.1) 131 (41.1) 101 (42.6) 
Systemic therapy    P = 0.426  P = 0.294 
    Chemotherapy 112 (19.5) 20 (16.4) 39 (19.5) 48 (23.8) 64 (20.0) 48 (20.1) 
    Endocrine therapy5 75 (13.1) 12 (9.8) 25 (12.5) 28 (13.9) 49 (15.3) 24 (10.0) 
    Both 18 (3.1) 3 (2.5) 9 (4.5) 6 (3.0) 11 (3.4) 7 (2.9) 
    No systemic therapy 369 (64.3) 87 (71.3) 127 (63.5) 120 (59.4) 196 (61.2) 160 (66.9) 

NOTE: Data are in n (%) unless otherwise indicated.

Abbreviations: HER2, human epidermal growth factor receptor 2; MST, mastectomy; BCS, breast conservative surgery.

Expression of HLA class I and infiltration of Treg

Microscopic quantification was successful in 94% (538 of 574) of tumors for HC10 and in 96% (548 of 574) for HCA2 (Fig. 1A and B). A total of 523 of 574 tumors (91%) could be quantified for both and were therefore available for total HLA class I expression evaluation. Three groups were defined for HLA class I expression: (a) HLA class I loss (both HCA2 and HC10 scored 0-5%), 23% of tumors; (b) HLA class I downregulation (either HCA2 or HC10 scored 0-5%), 38% of tumors; and (c) HLA class I expression (both HCA2 and HC10 scored 5-100%), 39% of tumors (Table 1).

Fig. 1.

Representative examples of immunohistochemical stainings. A, HCA2 score, 0-5%. B, HCA2 score, 75-100%. C, presence of Treg. Arrow, representative Foxp3-positive cell.

Fig. 1.

Representative examples of immunohistochemical stainings. A, HCA2 score, 0-5%. B, HCA2 score, 75-100%. C, presence of Treg. Arrow, representative Foxp3-positive cell.

Close modal

A total of 556 of 574 (97%) tumors could be evaluated for Treg infiltration (Fig. 1C). Tumors with absence of Treg (0 Treg per 10 high-power fields) and presence of Treg (≥1 Treg per 10 high-power fields) were seen in 57% and 43% of patients respectively (Table 1).

Prognostic value of HLA class I and Treg

To analyze the prognostic effect of HLA class I and Treg, all patients who did not receive any systemic therapy were analyzed. There were no statistically significant differences in outcome for relapse-free period (log-rank P = 0.27) or overall survival (log-rank P = 0.55) between different HLA class I expression levels (Fig. 2A and B). Treg showed no differences, neither in outcome for relapse-free period (log-rank P = 0.93) nor overall survival (log-rank P = 0.14) between intratumoral absence and presence (Fig. 3A and B). In contrast with the data in patients who did not receive systemic treatment, analysis of HLA class I expression in chemotherapy-treated patients showed statistically significant differences for relapse-free period between groups (log-rank P = 0.003; Fig. 2C). Of patients with expression of HLA class I, 68% were relapse free after 15 years compared with 51% and 30% for downregulation and loss of HLA class I expression, respectively. Infiltration of Treg showed, similarly to HLA class I, moderate differences in outcome between groups among chemotherapy-treated patients (log-rank P = 0.06; Fig. 3C). Patients with intratumoral infiltration of Treg had less relapses compared with patients with no infiltration of Treg. Cox proportional multivariate analysis was done with data from chemotherapy-treated patients, including the variables that showed a trend of influence on outcome (P < 0.1) in Cox proportional univariate analysis: lymph node status, HLA class I, and Treg (Table 2). This analysis revealed that lymph node status, HLA class I [P = 0.002; hazard ratio for downregulation, 2.11; 95% confidence interval (95% CI) for downregulation, 1.13-3.95; hazard ratio for loss, 3.34; 95% CI for loss, 1.67-6.67], and Treg (P = 0.01; hazard ratio, 2.04; 95% CI, 1.16-3.57) were all independent prognostic factors for relapse-free period among chemotherapy-treated patients.

Fig. 2.

HLA class I tumor expression and clinical outcome. Relapses over time (A) and overall survival (B) of nonsystemically treated patients. Relapses over time (C) and overall survival (D) of chemotherapy-treated patients.

Fig. 2.

HLA class I tumor expression and clinical outcome. Relapses over time (A) and overall survival (B) of nonsystemically treated patients. Relapses over time (C) and overall survival (D) of chemotherapy-treated patients.

Close modal
Fig. 3.

Treg tumor infiltration and clinical outcome. Relapses over time (A) and overall survival (B) of nonsystemically treated patients. Relapses over time (C) and overall survival (D) of chemotherapy-treated patients.

Fig. 3.

Treg tumor infiltration and clinical outcome. Relapses over time (A) and overall survival (B) of nonsystemically treated patients. Relapses over time (C) and overall survival (D) of chemotherapy-treated patients.

Close modal
Table 2.

Cox univariate and multivariate analyses for recurrence-free period of patients who did receive chemotherapy

nUnivariateMultivariate
HR (95% CI)PHR (95% CI)P
Age (y) 
    <40 25 1.00 0.370   
    40-50 57 1.01 (0.537-1.888)    
    50-60 30 0.67 (0.303-1.472)    
    >60 18 0.51 (0.183-1.413)    
Grade 
    I 15 1.00 0.887   
    II 57 1.12 (0.490-2.558)    
    III 57 0.99 (0.428-2.271)    
Histologic type 
    Ductal 117 1.00 0.453   
    Other 12 0.453 (0.594-3.209)    
Tumor stage 
    pT1 35 1.00 0.416   
    pT2 70 0.88 (0.491-1.560)    
    pT3/4 20 1.39 (0.657-2.950)    
Nodal stage 
    pN 38 1.00 0.002 1.00 0.001 
    pN+ 92 2.92 (1.480-5.741)  3.08 (1.539-6.179)  
Estrogen receptor 
    Negative 58 1.00 0.207   
    Positive 65 1.41 (0.828-2.390)    
Progesterone receptor 
    Negative 57 1.00 0.377   
    Positive 69 1.27 (0.750-2.138)    
Ki67 expression 
    Negative 101 1.00 0.866   
    Positive 23 0.68 (0.438-1.712)    
HER2 overexpression 
    Negative 82 1.00 0.497   
    Positive 17 1.29 (0.622-2.663)    
Local treatment 
    MST - radiotherapy 33 1.00 0.109   
    MST + radiotherapy 35 1.78 (0.889-3.548)    
    BCS + radiotherapy 62 1.01 (0.524-1.955)    
Endocrine therapy 
    Negative 112 1.00 0.501   
    Positive 18 0.76 (0.347-1.678)    
HLA 
    Expression 54 1.00 0.005 1.00 0.002 
    Downregulation 47 1.71 (0.929-3.159)  2.11 (1.127-3.947)  
    Loss 23 3.11 (1.577-6.116)  3.34 (1.671-6.670)  
Treg 
    >0 54 1.00 0.060 1.00 0.013 
    0 75 1.67 (0.979-2.857)  2.04 (1.164-3.568)  
nUnivariateMultivariate
HR (95% CI)PHR (95% CI)P
Age (y) 
    <40 25 1.00 0.370   
    40-50 57 1.01 (0.537-1.888)    
    50-60 30 0.67 (0.303-1.472)    
    >60 18 0.51 (0.183-1.413)    
Grade 
    I 15 1.00 0.887   
    II 57 1.12 (0.490-2.558)    
    III 57 0.99 (0.428-2.271)    
Histologic type 
    Ductal 117 1.00 0.453   
    Other 12 0.453 (0.594-3.209)    
Tumor stage 
    pT1 35 1.00 0.416   
    pT2 70 0.88 (0.491-1.560)    
    pT3/4 20 1.39 (0.657-2.950)    
Nodal stage 
    pN 38 1.00 0.002 1.00 0.001 
    pN+ 92 2.92 (1.480-5.741)  3.08 (1.539-6.179)  
Estrogen receptor 
    Negative 58 1.00 0.207   
    Positive 65 1.41 (0.828-2.390)    
Progesterone receptor 
    Negative 57 1.00 0.377   
    Positive 69 1.27 (0.750-2.138)    
Ki67 expression 
    Negative 101 1.00 0.866   
    Positive 23 0.68 (0.438-1.712)    
HER2 overexpression 
    Negative 82 1.00 0.497   
    Positive 17 1.29 (0.622-2.663)    
Local treatment 
    MST - radiotherapy 33 1.00 0.109   
    MST + radiotherapy 35 1.78 (0.889-3.548)    
    BCS + radiotherapy 62 1.01 (0.524-1.955)    
Endocrine therapy 
    Negative 112 1.00 0.501   
    Positive 18 0.76 (0.347-1.678)    
HLA 
    Expression 54 1.00 0.005 1.00 0.002 
    Downregulation 47 1.71 (0.929-3.159)  2.11 (1.127-3.947)  
    Loss 23 3.11 (1.577-6.116)  3.34 (1.671-6.670)  
Treg 
    >0 54 1.00 0.060 1.00 0.013 
    0 75 1.67 (0.979-2.857)  2.04 (1.164-3.568)  

Abbreviation: HR, hazard ratio.

Predictive value of HLA class I and Treg

To prove that HLA class I and Treg were statistically significant cooperating with chemotherapy, an interaction term was introduced in Cox regression analysis. This analysis showed that HLA class I (P < 0.001; hazard ratio for downregulation, 2.15; 95% CI for downregulation, 1.17-3.96; hazard ratio for loss, 3.15; 95% CI for loss, 1.92-5.15) and Treg (P < 0.001; hazard ratio, 2.47; 95% CI, 1.54-3.95) significantly interacted with chemotherapy administration. These data indicated that HLA class I expression and Treg tumor infiltration possess prognostic value, specifically in breast cancer patients who are treated with chemotherapy.

Our study showed that HLA class I and Treg are independent prognostic markers for chemotherapy-treated patients with substantial discriminative power. Variables that are able to determine which breast cancer patients may benefit from adjuvant chemotherapy are few (26). Known factors that tend to indicate better chemotherapy response are negative estrogen receptor, high tumor grade, and high proliferative activity, but their predictive value is marginal (27). In our study, independently of those factors, high levels of HLA class I expression and presence of Treg resulted in statistically significant less relapses over time. Most importantly, these results can be explained by underlying biology and correspond with results of previous studies.

In concordance with previous studies, downregulation and loss of HLA class I was frequently seen in our study (911). Previous studies indicate that breast cancer is immunogenic and induces tumor-associated antigen–specific CTL (28). These findings may imply that breast cancer cells with downregulation or loss of HLA class I expression escaped from immune destruction and therefore selectively grew out (29). This seems quite a common phenomenon in breast cancer, considering the fact that we and others found HLA class I downregulation or loss in more than half of the tumors. In addition, Tregs were found in a significant number of tumors. Tumors may either attract these immune-suppressing cells to evade attack from effector T cells, or Treg may consider tumor cells as normal cells and thus prevent immune attack. Our data indicate that the immune system is closely involved in the development of breast cancer. At the time of a clinically manifest tumor, the balance between immune attack and tumor growth obviously is at the site of the tumor (29).

We showed that expression levels of HLA class I had a specific prognostic effect but only in chemotherapy-treated patients. Previous studies on HLA class I expression in breast cancer did not stratify for systemic therapy. Three studies have evaluated HLA class I expression and its effect on prognosis in breast cancer (1012). Two studies found that HLA class I expression levels had no influence on the prognosis of patients, which is in concordance with our findings in patients that were not systemically treated (10, 12). Our study also showed that infiltration of Treg was a predictive marker for chemotherapy response in breast cancer patients. These finding are supported by Ladoire et al. (16), who found that the number of Treg declined due to chemotherapy, showing that chemotherapy affects Treg and thus may counteract by restrained CTL. More importantly, complete absence of Treg after chemotherapy administration resulted in a better response with higher rates of pathologic complete response, further supporting our findings of a predictive role of Treg. Other studies have shown that infiltration of Treg in breast tumors resulted in a worse prognosis in terms of relapses and survival (15, 30). Our study could not statistically prove such a relation in patients who did not receive systemic treatment. To unravel the complex tumor–immune system interactions during tumor development, further studies are needed.

The specific prognostic effects found for HLA class I and Treg among chemotherapy-treated patients can be explained by the following biological explanation. In our population, choice of chemotherapy is composed of cyclophosphamide, which positively influences host immune responses against cancer (3133). It is hypothesized that several mechanism are the basis for this phenomenon: enhanced homeostatic expansion of antigen-specific T cells by creation of a niche in the immune system, stimulation of dendritic cells, induction of T-cell growth factors such as type I IFNs, and selective elimination of Treg (3133). Ceasing of Treg through cyclophosphamide effects results, among other things, in enhanced expansion and function of responding of CTL (32, 33). Ladoire et al. (16) found that, after preoperative chemotherapy, absolute numbers of tumor-infiltrating Treg significantly declined and numbers of effector T cells and CTL remained stable. In addition, a pathologic complete response was associated with a combination of absence of infiltration of Treg and presence of CTL after chemotherapy. In our study, this phenomenon was associated only in tumors that retained HLA expression, suggesting that, upon counteraction of Treg, CTLs are able to affect tumor metastases development.

In summary, HLA class I and Treg have an independent prognostic effect for chemotherapy-treated patients, which can be explained by underlying biology. Both factors resulted in a very high differentiation in sensitivity to chemotherapy. Predictive factors for chemotherapy response in breast cancer are highly necessitated. Therefore, we conclude that HLA class I and Treg are candidate markers for further investigation in randomized studies and may be applied for chemotherapy response prediction.

No potential conflicts of interest were disclosed.

We thank J. Molenaar for his help with the database, K. van de Ham for pictures of representative immunohistochemical stainings, and colleagues at the research laboratory of the surgery department at the Leiden University Medical Center for their help and advice.

Grant Support: Financial support from the Dutch Cancer Society (UL 2007-3968).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1
Early Breast Cancer Trialists' Collaborative Group
. 
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
.
Lancet
2005
;
365
:
1687
717
.
2
Goldhirsch
A
,
Wood
WC
,
Gelber
RD
,
Coates
AS
,
Thurlimann
B
,
Senn
HJ
. 
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
.
Ann Oncol
2007
;
18
:
1133
44
.
3
Van Pel
A
,
Boon
T
. 
Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis
.
Proc Natl Acad Sci U S A
1982
;
79
:
4718
22
.
4
Zitvogel
L
,
Tesniere
A
,
Kroemer
G
. 
Cancer despite immunosurveillance: immunoselection and immunosubversion
.
Nat Rev Immunol
2006
;
6
:
715
27
.
5
Mehta
AM
,
Jordanova
ES
,
Kenter
GG
,
Ferrone
S
,
Fleuren
GJ
. 
Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma
.
Cancer Immunol Immunother
2008
;
57
:
197
206
.
6
Menon
AG
,
Morreau
H
,
Tollenaar
RA
, et al
. 
Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients
.
Lab Invest
2002
;
82
:
1725
33
.
7
Speetjens
FM
,
de Bruin
EC
,
Morreau
H
, et al
. 
Clinical impact of HLA class I expression in rectal cancer
.
Cancer Immunol Immunother
2008
;
57
:
601
9
.
8
Algarra
I
,
Garcia-Lora
A
,
Cabrera
T
,
Ruiz-Cabello
F
,
Garrido
F
. 
The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape
.
Cancer Immunol Immunother
2004
;
53
:
904
10
.
9
Cabrera
T
,
Angustias
FM
,
Sierra
A
, et al
. 
High frequency of altered HLA class I phenotypes in invasive breast carcinomas
.
Hum Immunol
1996
;
50
:
127
34
.
10
Gudmundsdottir
I
,
Gunnlaugur
JJ
,
Sigurdsson
H
,
Olafsdottir
K
,
Tryggvadottir
L
,
Ogmundsdottir
HM
. 
Altered expression of HLA class I antigens in breast cancer: association with prognosis
.
Int J Cancer
2000
;
89
:
500
5
.
11
Madjd
Z
,
Spendlove
I
,
Pinder
SE
,
Ellis
IO
,
Durrant
LG
. 
Total loss of MHC class I is an independent indicator of good prognosis in breast cancer
.
Int J Cancer
2005
;
117
:
248
55
.
12
Redondo
M
,
Garcia
J
,
Villar
E
, et al
. 
Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis
.
Hum Pathol
2003
;
34
:
1283
9
.
13
Salama
P
,
Phillips
M
,
Grieu
F
, et al
. 
Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer
.
J Clin Oncol
2009
;
27
:
186
92
.
14
Wolf
D
,
Wolf
AM
,
Rumpold
H
, et al
. 
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer
.
Clin Cancer Res
2005
;
11
:
8326
31
.
15
Bates
GJ
,
Fox
SB
,
Han
C
, et al
. 
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse
.
J Clin Oncol
2006
;
24
:
5373
80
.
16
Ladoire
S
,
Arnould
L
,
Apetoh
L
, et al
. 
Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells
.
Clin Cancer Res
2008
;
14
:
2413
20
.
17
Perez
SA
,
Karamouzis
MV
,
Skarlos
DV
, et al
. 
CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients
.
Clin Cancer Res
2007
;
13
:
2714
21
.
18
Seitz
C
,
Uchanska-Ziegler
B
,
Zank
A
,
Ziegler
A
. 
The monoclonal antibody HCA2 recognises a broadly shared epitope on selected classical as well as several non-classical HLA class I molecules
.
Mol Immunol
1998
;
35
:
819
27
.
19
Sernee
MF
,
Ploegh
HL
,
Schust
DJ
. 
Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents
.
Mol Immunol
1998
;
35
:
177
88
.
20
Hutter
H
,
Hammer
A
,
Blaschitz
A
, et al
. 
Expression of HLA class I molecules in human first trimester and term placenta trophoblast
.
Cell Tissue Res
1996
;
286
:
439
47
.
21
Perosa
F
,
Luccarelli
G
,
Prete
M
,
Favoino
E
,
Ferrone
S
,
Dammacco
F
. 
β2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide
.
J Immunol
2003
;
171
:
1918
26
.
22
Hill
JA
,
Feuerer
M
,
Tash
K
, et al
. 
Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature
.
Immunity
2007
;
27
:
786
800
.
23
Generali
D
,
Bates
G
,
Berruti
A
, et al
. 
Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients
.
Clin Cancer Res
2009
;
15
:
1046
51
.
24
Chew
SF
,
Kanaan
C
,
Tait
BD
. 
HLA expression and cancer—14th IHIWS immunohistochemistry quality control exercise exchange results
.
Tissue Antigens
2007
;
69 Suppl 1
:
248
51
.
25
Putter
H
,
Fiocco
M
,
Geskus
RB
. 
Tutorial in biostatistics: competing risks and multi-state models
.
Stat Med
2007
;
26
:
2389
430
.
26
Goldhirsch
A
,
Wood
WC
,
Gelber
RD
,
Coates
AS
,
Thurlimann
B
,
Senn
HJ
. 
Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer
.
J Clin Oncol
2003
;
21
:
3357
65
.
27
Ross
JS
,
Linette
GP
,
Stec
J
, et al
. 
Breast cancer biomarkers and molecular medicine
.
Expert Rev Mol Diagn
2003
;
3
:
573
85
.
28
Sotiropoulou
PA
,
Perez
SA
,
Iliopoulou
EG
, et al
. 
Cytotoxic T-cell precursor frequencies to HER-2 (369-377) in patients with HER-2/neu-positive epithelial tumours
.
Br J Cancer
2003
;
89
:
1055
61
.
29
Ferrone
S
,
Whiteside
TL
. 
Tumor microenvironment and immune escape
.
Surg Oncol Clin N Am
2007
;
16
:
755
74
,
viii
.
30
Gobert
M
,
Treilleux
I
,
driss-Vermare
N
, et al
. 
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome
.
Cancer Res
2009
;
69
:
2000
9
.
31
Dudley
ME
,
Wunderlich
JR
,
Robbins
PF
, et al
. 
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
.
Science
2002
;
298
:
850
4
.
32
Ghiringhelli
F
,
Larmonier
N
,
Schmitt
E
, et al
. 
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative
.
Eur J Immunol
2004
;
34
:
336
44
.
33
Proietti
E
,
Greco
G
,
Garrone
B
, et al
. 
Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice
.
J Clin Invest
1998
;
101
:
429
41
.